Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cyterix Pharmaceuticals

Request full access

Oncology prodrugs targeting tumor-specific enzymes for cancer therapy

San Francisco, United StatesFounded 2010Biotech & Life Sciences

About Cyterix Pharmaceuticals

Cyterix Pharmaceuticals was a biotechnology company focused on developing novel, small molecule cancer therapeutics through a specialized prodrug approach. Founded in April 2010 by Professor Steven A. Everett, the late Dr. John Curd, and Professor Paul Ortiz de Montellano, the company was built on a foundation of deep expertise in prodrug development and cytochrome P450 biochemistry. Professor Everett, who served as President and CEO, invented the company's core OncoCYP™-targeted prodrug discovery approach. This technology was developed at the University of Dundee in Scotland with support from Cancer Research UK and was exclusively licensed to Cyterix.

The company's business model centered on its proprietary technology platform, which was designed to create anticancer prodrugs activated selectively by extra-hepatic cytochrome P450 enzymes. These enzymes, referred to as OncoCYP™ enzymes, are significantly over-expressed in a wide range of solid and hematologic cancers but are not present in normal tissues. This tumor-specific activation aimed to overcome the dose-limiting toxicities of conventional chemotherapy by delivering potent cytotoxic agents directly to cancer cells, thereby improving safety and efficacy. Cyterix's strategy was to advance its lead compounds, which used approved drugs as 'warheads', through IND-enabling studies and into Phase 1 clinical trials to establish proof-of-concept.

In June 2011, Cyterix announced a $9.2 million Series A financing round from The Column Group and SV Life Sciences to fund these developments. The company raised a total of approximately $8.8 million over two rounds. Despite its promising technology and initial funding, Cyterix Pharmaceuticals is no longer in business.

Source: Dealroom company data

At a glance

Founded
2010
Headquarters
San Francisco, United States
Sector
Biotech & Life Sciences

Cyterix Pharmaceuticals in the San Francisco ecosystem

Live from Dealroom

The Cyterix Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • SV Health Investors
  • The Column Group
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Francisco HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cyterix Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cyterix Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.